Common myths about hair loss and which natural remedies can grow it back
When it comes to hair loss, there are as many myths about it as there are treatments for it. An expert broke down common ...
Myriad Genetics announce collab with Lumea
Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to ...
DNA Testing Market Increasing Size, Demand, Growth Rate, And Forecast 2033 - Emergen Research
Emergen Research Logo The DNA Testing market is expected to grow from an estimated USD 12.51 billion in 2024 to USD 81.82 billion in 2033, ...
Myriad Genetics (NASDAQ:MYGN) Given New $14.00 Price Target at Piper Sandler
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price cut by analysts at Piper Sandler from $24.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The brokerage ...
Consumer Genomics Market Size to Hit USD 10.8 Billion by 2032, Growing at a 24.6% CAGR - SNS Insider
Consumer Genomics Market growth is driven by rapid advancements in genetic testing technologies, declining sequencing costs, and increasing consumer awarenessPune, Jan. 31, 2025 (GLOBE NEWSWIRE) -- ...
Zacks.com on MSN6d
Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now?
QIAGEN N.V.’s QGEN long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company sees ...
Myriad Genetics price target lowered to $14 from $24 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...